Iskalni niz:
išči po
išči po
išči po
išči po
Vrsta gradiva:
Jezik:
Št. zadetkov: 2
Novel nastorazepide-based radioligands demonstrate excellent cholecystokinin-2 receptor targeting and theranostic potential
Lennart Bohrmann, Doroteja Novak, Marko Krošelj, Raghuvir H. Gaonkar, Francesca Porto, Fani Melpomeni, Petra Kolenc-Peitl, Marko Anderluh, Marko Anderluh, Rosalba Mansi, Rosalba Mansi
Izvirni znanstveni članek
Oznake: cholecystokinin-2 receptor antagonists;CCK2R antagonists;nastorazepide;radioligands;SPECT/CT;peptide receptor radionuclide therapy;
Radiolabeled gastrin antagonists are emerging as a new tool for the diagnosis and treatment of cholecystokinin-2 receptor (CCK2R) expressing tumors such as medullary thyroid carcinoma and small cell lung cancer, overcoming limitations of agonist-based ligands. In this study, the CCK2R antagonist nas ...
Leto: 2026 Vir: Repozitorij Univerze v Ljubljani (RUL)
Development of the 99mTc-labelled SST2 antagonist TECANT-1 for a first-in-man multicentre clinical study
Doroteja Novak, Barbara Janota, Anton Amadeus Hörmann, Agnieszka Sawicka, Marko Krošelj, Alicja Hubalewska-Dydejczyk, Melpomeni Fani, Renata Mikolajczak, Petra Kolenc-Peitl, Clemens Decristoforo, Piotr Garnuszek
Izvirni znanstveni članek
Oznake: tehnecij-99m;antagonisti receptorjev somatostatina;formulacija kompleta;toksičnost enkratnega odmerka;SPECT;radiofarmacevtiki;nevroendokrine neoplazme;technetium-99m;somatostatin receptor antagonists;kit formulation;single dose toxicity;radiopharmaceuticals;neuroendocrine neoplasms;
Broad availability and cost-effectiveness of 99Mo/99mTc generators worldwide support the use, and thus the development, of novel 99mTc-labelled radiopharmaceuticals. In recent years, preclinical and clinical developments for neuroendocrine neoplasms patient management focused on somatostatin recepto ...
Leto: 2023 Vir: Fakulteta za farmacijo (UL FFA)
Št. zadetkov: 2
Ključne besede:
Leto izdaje:
Avtorji:
Repozitorij:
Tipologija:
Jezik: